MedTrace Logo

Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru

NCT05361486 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 187

Last updated 2026-03-20

No results posted yet for this study

Summary

The goal of this study is to evaluate the operational feasibility of using a new treatment algorithm for Malaria Vivax in Peru.

The implementation package includes the following interventions:

* A revised vivax treatment algorithm that incorporates new Radical Cure tools (G6PD test + Tafenoquine or Primaquine)
* The training of Health Care Providers ( HCPs) in the revised algorithm and the use of the new RC tools
* Patient counselling
* A follow-up visit at Day 3 \[+2 days\] for patients after treatment start
* Accompanying supporting measures: job aids, strengthening of supervision and PV processes

Conditions

  • Malaria, Vivax

Interventions

DRUG

Tafenoquine (TQ)

G6PD test after Malaria Vivax diagnosis

Sponsors & Collaborators

  • Universidad Peruana Cayetano Heredia

    collaborator OTHER

  • UNITAID

    collaborator OTHER

  • ICON plc

    collaborator INDUSTRY

  • Medicines for Malaria Venture

    lead OTHER

Principal Investigators

  • Elmer Alejandro Llanos Cuentas, MD, PhD · Universidad Peruana Cayetano Heredia (UPCH)

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-28
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Peru

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05361486 on ClinicalTrials.gov